Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Daptomycin

Daptomycin

Lipopeptide cyclic (IV)

MRSABacteremiaCPKNo pneumonia

Indication

MRSA bacteremia β€’ endocarditis β€’ osteomyelitis β€’ VRE bacteremia selected

At a glance

INDICATIONS (CORE USE)

MRSA bacteremia / SSTI / endocarditis (right-sided selected) β€” **inactivated by pulmonary surfactant β†’ DO NOT use for pneumonia**; **CPK monitoring**; statin hold.

ADULT DOSE (STANDARD)

4–6 mg/kg IV q24h SSTI; 6–10 mg/kg q24h bacteremia/endocarditis β€” **indication-specific**

MAX DOSE

High-dose protocols for VRE (12 mg/kg) β€” ID stewardship only

Route

IV

PEDIATRIC DOSE

Pediatric approval limited β€” specialist

Do not miss

Must-not-miss safety points

Major warning

- **Contraindicated for pneumonia** β€” surfactant inactivation β†’ clinical failure - **CPK elevation / rhabdomyolysis** β€” weekly CPK; hold statins - Eosinophilic pneumonia rare β€” hypoxia + fever β†’ stop drug - Muscle pain β€” evaluate CPK

Indications

USE IF: MRSA bacteremia, complicated SSTI, right-sided endocarditis when susceptible. AVOID IF: Pneumonia as primary site; trivial infection needing oral therapy.

Primary

  • MRSA complicated SSTI / bacteremia (including right-sided endocarditis per guideline)
  • Vancomycin-intolerant MRSA infection when daptomycin susceptible

Secondary

  • VRE bacteremia at elevated doses β€” ID-directed
  • Osteomyelitis MRSA when long IV course chosen

Other

  • Prosthetic joint infection combinations β€” specialist

Dosing

STANDARD (ADULT PO)

4–6 mg/kg IV q24h (SSTI) β†’ 6–10 mg/kg q24h (bacteremia/endocarditis per ID)

ADULT DOSE

4–6 mg/kg q24h SSTI; 6 mg/kg q24h bacteremia standard; 8–10 mg/kg endocarditis/bacteremia persistent β€” ID

PEDIATRIC DOSE

If used β€” pediatric trial dosing only.

MAX DOSE

12 mg/kg q24h VRE selected protocols β€” pharmacy/ID

Practical Note

Renal adjustment CrCl <30 per label (q48h some references).

Warnings

Clinical warnings

  • Myopathy
  • Peripheral neuropathy prolonged use

Adverse effects

  • CPK elevation
  • constipation
  • insomnia

Contraindications

  • Pneumonia treatment (relative contraindication β€” ineffective)

Drug interactions

  • Statins β€” hold during therapy
  • Warfarin β€” monitor INR

Special populations

Pediatrics

Pediatric approval limited β€” specialist

Pregnancy

Animal skeletal effects β€” human use only if necessary

Lactation

unknown.

Renal impairment

CrCl <30 β†’ label-based interval extension. **CrCl scaffold (FMBM β€” titrate to FDA/SFDA label + institutional pharmacy nomogram):** - **CrCl β‰₯50** β†’ q24h usual mg/kg (per label) - **CrCl 10–50** β†’ per label (often q24h until CrCl **<30** β€” verify monograph) - **CrCl <10** β†’ **q48h** typical; monitor CPK + renal function; **HD** redose per pharmacy

Hepatic impairment

No routine adjustment.

Elderly

CPK baseline; fall risk.

Administration

IV infusion; compatible with NS often β€” check product.

Monitoring

  • Monitor: - Baseline then **weekly CPK** (or sooner if myalgia) β†’ hold **statins** when feasible - New hypoxia + infiltrate on therapy β†’ **stop daptomycin** β†’ evaluate eosinophilic pneumonia - MRSA bacteremia β†’ source control + ID follow-up (not reliable pneumonia monotherapy) - CPK weekly (more if symptoms) - Daily clinical review MRSA bacteremia β€” echo if prolonged - Oxygen saturation if new lung infiltrate on daptomycin β€” eosinophilic pneumonia
  • Recheck: - No clinical improvement at 48–72h β†’ reassess diagnosis, resistance, source control, and drug interactions - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)

Overdose / toxicity

Clinical Picture

**Life-threatening (first):** **rhabdomyolysis** with **AKI** / hyperK+; **ARDS** (eosinophilic pneumonia). **Secondary:** isolated CPK rise.

Immediate Actions

Stop daptomycin β†’ CPK, BMP, urine myoglobin if rhabdo suspected; IV fluids

Antidote

No specific antidote; treat complications (e.g. anaphylaxis β†’ epinephrine per ACLS)

Decontamination

N/A

Escalation

Compartment syndrome, rising CK with AKI, ARDS β†’ **ICU**; **severe AKI β†’ hemodialysis** supportive; daptomycin clearance enhanced by HD β€” redose per pharmacy

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

**Great for blood + bone** β€” **terrible for lung** (don’t treat HAP β€œbecause MRSA”). **CPK + stop statin**. Higher mg/kg for endocarditis/bacteremia.

Clinical pearls

Stewardship: vancomycin often first for bacteremia β€” dapto when intolerance or persistent. Source control still mandatory. *Stewardship (all antimicrobials):* Empiric choice β†’ syndrome severity + **local antibiogram**; shortest effective course.

Stewardship & safety

  • Never pneumonia
  • CPK weekly
  • Hold statin

Pharmacokinetics

Renal elimination; long half-life q24h; penetrates bone well.

Mechanism of action

Depolarizes membrane β€” rapid bactericidal; Ca-dependent.

Common brand names

Saudi Arabia

Cubicin, Daptomycin

Global

(placeholder β€” verify local formulary)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Empiric choice β†’ tie to syndrome, severity, and local antibiogram β€” not habit.
  • IV β†’ PO step-down when oral bioavailability and susceptibility allow.
  • Do not use antibiotics for uncomplicated viral illness β€” stewardship.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • Sanford Guide
  • IDSA / ESCMID (indication-specific)
  • Local antimicrobial stewardship / hospital formulary
  • FDA / SFDA / regional product labeling
  • Sanford Guide
  • IDSA / ESCMID (indication-specific)
  • Local antimicrobial stewardship / hospital formulary
  • FDA / SFDA / regional product labeling

Do not miss

  • Uncomplicated viral URI/bronchitis β†’ antibiotics rarely indicated
  • Narrow or stop when susceptibilities + clinical stability allow
  • Prescribing for pneumonia β†’ predictable failure.
  • Rhabdo with statin co-use.
  • Never pneumonia
  • CPK weekly
  • Hold statin